An Analysis Finds Shingrix is Highly Effective for Preventing Shingles in Seniors

An Analysis Finds Shingrix is Highly Effective for Preventing Shingles in Seniors

A real-world analysis shows Shingrix effectively prevents shingles in adults over the age of 65, including immunocompromised people.

Shingles is a viral infection that occurs when the varicella-zoster virus (VZV) reactivates in the body, presenting as a rash with painful blisters.

According to the CDC, shingles is more common in adults over 50, with 5-30% of patients experiencing post-herpetic neuralgia (PHN), a long-lasting nerve pain.

Shingrix, a recombinant zoster vaccine (RZV) manufactured by GSK, provides better protection with two doses than one.

Two doses provide better protection than one.

Author's summary: Shingrix prevents shingles in seniors.

more

Managed Healthcare Executive Managed Healthcare Executive — 2025-10-14

More News